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MDMXThe p53 tumor suppressor protein is involved in regulating a wide variety of stress responses, from senes-
cence and apoptosis to more recently discovered roles in allowing adaptation to metabolic and oxidative
stress. After 34 years of research, signiﬁcant progress has been made in unraveling the complexity of the
p53 network, and it is clear that the regulation of p53 protein stability is critical in the control of p53 activity.
This article focuses on our current understanding of how the level and activity of p53 is controlled by this
seemingly simple mechanism. This article is part of a Special Issue entitled: Ubiquitin–Proteasome System.
Guest Editors: Thomas Sommer and Dieter H. Wolf.
© 2013 Elsevier B.V. All rights reserved.1. Ubiquitination — a complex signal
While ubiquitination was initially identiﬁed as the key mechanism
in marking misfolded or surplus protein molecules for degradation, it
soon became clear that it is far more than just a general mechanism to
mark obsolete proteins for degradation. Indeed, ubiquitination is now
recognized as a highly regulated, ﬂexible and reversible process that
can signal multiple responses, from degradation to changes in activi-
ty, re-localization or changes in the histone code. This high band-
width in signaling power is achieved by the complex nature of the
ubiquitin signal itself, which reﬂects not only the position of the
ubiquitin mark on the substrate protein, but also the length and archi-
tecture of the ubiquitin chain.
While conjugation of a single ubiquitin to a target protein can pro-
vide a signaling tag (for example to alter subcellular localization or
mark membrane proteins for recycling), the formation of ubiquitin
chains provides greater diversity in signaling potential. Ubiquitin
modiﬁcations are assembled by a hierarchical cascade comprising
ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes
(E2) and ubiquitin-ligating enzymes (E3) [1]. The E3 ligase is respon-
sible for substrate and target lysine speciﬁcity, and also determines
the linkage type within the poly-ubiquitination chain, aided to some
extent by the E2 enzyme [2].
Ubiquitin can be interlinked via any of its lysines (K6, K11, K27,
K29, K33 K48 and K63) and through the amino terminal methio-
nine. The best-characterized poly-ubiquitin chain is formed via K48
linkages. Chains of four or more ubiquitin molecules interlinked viatin–Proteasome System. Guest
ousden).
rights reserved.K48 lead to degradation of the marked protein [3]. In contrast, poly-
ubiquitination via K63 predominantly regulates signaling through
other pathways that can lead, for example, to NF-κB activation [4],
the regulation of different steps in the DNA repair program [5]
and the control of membrane trafﬁcking [6,7]. In addition to this,
K63 ubiquitin chains may also act as a 26S proteasome targetting
signal.
Other poly-ubiquitin chains (reviewed in [8]) include linkages via
the other lysines in ubiquitin, branched chains formed through the
use of mixed lysines and linear ubiquitin chains linked through the
N-terminalmethionine and the C-terminal glycine of adjacent ubiquitins.
The functional outcome of these modiﬁcations — some of which
may be relatively abundant — is less well understood, although
they have been shown to drive signaling, provide novel binding
sites for partner proteins and target proteolysis. Overall, the impact
of these modiﬁcations on substrate proteins is likely to be pro-
found, and their identiﬁcation has opened new and exiting areas
of research.2. p53: it's all about stability
The primary function of p53 is as a transcription factor, activating
and repressing the expression of a large number of target genes [9].
Non-transcriptional activities of p53, for example in the regulation
of apoptotic signals at the mitochondria, have also been described
[10]. In healthy cells, p53 plays a pivotal role in responding to onco-
genic stress signals and helps to keep cells metabolically stable [9].
The importance of p53 is highlighted by the fact that it is frequently
altered in human cancers [11,12], indeed even tumors that retain
wild type p53 are often compromised in their ability to activate
the p53 pathway. Acute activation of p53 leads to numerous re-
sponses that prevent further cell division, including cell cycle arrest,
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incipient cancer cells. However, these activities of p53 must be carefully
regulated under normal unstressed conditions to allow cell growth and
division. Various aspects of p53 expression, subcellular localization and
activity are actively regulated, and a large number of post-translational
modiﬁcations on p53 have been shown to modulate these functions
[13]. Key to the regulation of p53 is the control of the stability of the
p53 protein, orchestratedmainly through a network of ubiquitination re-
actions (Fig. 1). In addition, there is evidence of continuous degradation
of p53 by the 20S core catalytic chamber of the proteasome,which can be
inhibited by the detoxifying enzyme NQO1 (reviewed in [14]). This rela-
tionship links the stress response to ROS (which induces NQO1 expres-
sion) with stabilization of p53, which is itself a potent regulator of
intracellular ROS. However, while this mechanism of p53 degradation
depends on the proteasome, it is independent of ubiquitin.
Constantly cycling between producing and then degrading p53 is an
energy costly way of maintaining low levels of p53, but it allows for a
very short response time after a stress signal. The p53 pathway there-
fore remains poised to an extent that would not be possible if p53 in-
duction depended on regulated transcription, splicing, translation and
folding. Spontaneous pulses of p53 accumulation can be detected in
normal proliferating cells, although these do not reach a threshold nec-
essary for full activation of a p53 response [15]. This system has been
proposed to allow growth under normal conditions while ensuring a
rapid reaction to stress that might otherwise prove harmful to both
the cell and – ultimately – the whole organism.
3. MDM2/MDMX
A key negative regulator of p53 is MDM2 and its close homolog
MDMX. Complete loss of eitherMDM2 orMDMX results in an early em-
bryonic lethality that is p53 dependent [16–18], demonstrating the im-
portance of these regulators of p53 function.While the lethality of both
mice indicates that the activities of MDM2 and MDMX are not redun-
dant, MDMX deﬁcient animals can be rescued by overexpression of
MDM2, suggesting some overlap in function [19], although the absence
of MDM2 cannot be compensated by overexpression of MDMX [20].
Furthermore, loss of MDMX appears to be somewhat less deleterious
than loss of MDM2, with some adult tissues showing no phenotype fol-
lowing MDMX deletion [21].
Both MDM2 and MDMX bind to the N-terminal transactivation do-
main of p53, and can inhibit p53's transcriptional activity directly by
blocking the binding of co-activators such as p300 and recruitment of
repressors such as histone deacetylases and lysine methyltransferases
[22–24]. MDM2 binding has also been shown to promote a conforma-
tional shift in p53, rendering it unable to bind DNA and so carry out
its normal transcriptional activities [25,26]. However, much more efﬁ-
cient regulation of p53 activity is achieved by the ability of the MDM2
to function as a RING ﬁnger E3 ligase and target p53 for degradation
[27,28]. While MDM2 can homodimerize and poly-ubiquitinate p53,
at physiological concentrations the MDM2 homo-dimer seems to pre-
dominantly mono-ubiquitinate p53 [29]. MDMX also contains a RING
domain, and although it has no intrinsic ubiquitin E3 ligase activity,
MDM2 and MDMX dimerize efﬁciently through RING/RING interac-
tions. Importantly, this heterodimerization of MDM2 and MDMX plays
an important role in the regulation of p53 stability, at least in the em-
bryo [30,31]. So, although both MDM2 and MDMX can exert indepen-
dent regulation on p53, there is growing evidence to support the idea
that MDMX contributes to the degradation of p53, and that the
MDM2/MDMX complex constitutes the principal active E3 ligase for
p53 [29]. MDM2 modiﬁes p53 predominantly on six lysine residues lo-
cated at the C-terminus of the protein (K370, K372, K373, K381, K382,
and K386 [32]) to target it for degradation. Both the RING domains
and C-terminal tails of MDM2 and MDMX are critical for this activity
[33], and either deletion [34] or extension [35] of the MDM2 tail sub-
stantially inhibits E3 activity. The exact role of the C-terminal tail isnot fully established, although by analogy with other RING domain
E3s it seems possible that the tail of MDM2 or MDMX docks into the
RING of the partner protein in the dimer, to form a binding site for the
ubiquitin loaded E2 [36]. Finally, MDM2 is also involved in the subse-
quent post-ubiquitination step that brings p53 to the proteasome [37].
Interestingly, despite the clear evidence supporting a role for
MDM2/MDMX in the negative regulation of p53 activity, a number
of studies suggest that under some circumstances p53 function
could be stimulated by MDM2 or MDMX. MDM2 can bind p53
mRNA, resulting in enhanced p53 expression — an activity that also
depends on the RING domain of MDM2 [38]. An MDM2 RING domain
point mutant, which lacks E3 activity, serves to enhance p53's activity
towards several target genes by enhancing the recruitment of p300 —
a transcriptional co-activator [39].
It is also important to remember that MDM2/MDMX speciﬁc
ubiquitination of p53 does not necessary lead to degradation of p53,
but can have different outcomes depending on the chain length and
chain linkage. Lower levels of MDM2, or maybe the availability of
MDM2 homodimers, causes mono ubiquitination [29] and nuclear ex-
port of p53 [40]. MDMX can also independently help to promote the
stabilization of cytoplasmic p53 in an active conformation [41]. Interest-
ingly the accumulation of cytoplasmic p53 is an activity that is exhibited
by several E3s (see below and Table 1), consistent with the importance
of the regulation of p53's subcellular localization in the control of the
p53 response. Clearly, removal from the nucleus inhibits p53's tran-
scriptional activity, and once in the cytoplasm, p53 can be further
ubiquitinated and degraded by p300, an E4 ligase, as discussed later.
However, a number of different functions for cytoplasmic p53 have
also been described that play a positive role in regulating processes
such as apoptosis, autophagy and metabolism [42–44]. Cytoplasmic
p53 also interacts with the ubiquitin ligase CUL9/PARC [45], resulting
in the cytoplasmic sequestration of p53. However, this activity is not de-
pendent on ubiquitination of p53, and again leads to enhanced apopto-
sis [46].
MDM2/MDMX can also promote the modiﬁcation of p53 with
other ubiquitin-like proteins. Neddylation by MDM2 occurs on three
C-terminal lysines (K370, K372, K373) of p53, resulting in the inhibi-
tion of transcriptional activity [47] and nuclear export [48]. However,
this modiﬁcation does not seem have a signiﬁcant effect on the
degradation of p53. As with ubiquitination, the MDM2/MDMX
heterodimer seems to be the preferred Nedd8 E3 ligase complex
and MDMX can rescue E3 ligase deﬁcient point mutations of MDM2
[49]. Apart from MDM2/MDMX, FBXO11 has also been reported to
modify p53 with Nedd8, again leading to reduced transcriptional ac-
tivity of p53 [50].
p53 is also modiﬁed speciﬁcally on lysine 386 with the small
ubiquitin likemodiﬁer SUMO,with evidence that various SUMOE3s, in-
cluding the PIAS family and Topors, can target this modiﬁcation of p53
[51]. Interestingly, MDM2 has also been shown to promote both the
SUMO-1 [52] and SUMO-2/3 conjugation of p53 [53], in a process that
does not require the RING domain of MDM2 and which can be further
increased by MDM2 binding proteins like p14ARF and L11 [52,54].
The consequences of p53 SUMOylation remain unclear, with evidence
for both a promotion and inhibition of transcriptional activity [54–56]
and regulation of subcellular localization [52,54,57,58]. Overall, only a
small fraction of p53 (probably less than 5%) is found to be modiﬁed
by SUMO-1 at a steady state in cells [55,59,60] and the overall outcome
of SUMOylation on p53 is likely to be dependent on the context of other
modiﬁcations of p53 [57] and the choice of experimental model.
Taken together, therefore, it seems clear thatMDM2 andMDMX can
modulate p53 through several mechanisms, both independently and
working in partnership. Mice carrying mutations in MDM2 or MDMX
that speciﬁcally inhibit E3 activity and dimerizationwithout preventing
the interaction of these proteins with p53 show phenotypes similar to
the complete deletion ofMDM2orMDMX, [30,31,61], indicate that sim-
ply the binding of MDM2 or MDMX to p53 is not enough to keep it
Table 1
Ubiquitin ligases and de-ubiquitinating enzymes that modify p53.
Enzyme Class Selected references
(also see text)




In vitro In cells
MDM2 E3 [27,28], see text RING K48 K370, K372, K373, K381,
K382, and K386, more in vitro
Repressed transcriptional
activity, degradation, nuclear export
✓ ✓ Mouse





Arf-BP1 E3 [196] HECT Degradation ✓ ✓ Mouse
Carpi E3 [210] RING Degradation ✓
Carp2 E3 [210] RING Degradation ✓
CHIP E3 [198] U box Degradation ✓ ✓ Mouse
Copi E3 [125] RING K48 Degradation ✓ ✓
Cul1 E3 [217] RING Degradation ✓ ✓ Mouse
Cul4a E3 [219,220,226] RING Degradation ✓ Mouse
Cul5 E3 [221] RING K48 Degradation ✓
Cul7 E3 [223] RING Repressed transcriptional activity ✓ ✓
Cul9/PARC E3 [46] RING Cytoplasmic sequestration, apoptosis Mouse
Hades E3 [208] RING K24 Degradation ✓ ✓
MSL2 E3 [207] RING K351 and K357 Nuclear export ✓
Pirh2 E3 [124,193,195] RING K48 K101, K164, K292, K305,
K357 K382 and K386
Degradation ✓ ✓ Mouse
Synoviolin E3 [211] RING Degradation, nuclear export ✓ ✓ Drosophila
Topors E3 [212] RING Degradation ✓ ✓
Trim24 E3 [200] RING Degradation ✓ ✓ Drosophila
Trim28 E3 [214] RING Degradation ✓
Trim39 E3 [215] RING Degradation ✓
wwpl E3 [206] HECT Stabilization, nuclear export ✓ ✓
UBC13 E2 [209,269] K63 Stabilization as monomer (less activity) ✓
E4F1 E4 [204] K48 K319, K320, K321 Modulated transcriptional activity ✓ ✓
Gankyrin E4 [179] Degradation ✓ ✓
p300/CBP E4 [176,268] Degradation ✓ ✓
UBE4B E4 [177,270] U-Box Degradation ✓ ✓
Yin Yang 1 E4 [180] Degradation ✓ ✓
Hausp DUB [233,235,237] Degradation (stabilization of MDM2/X) ✓ ✓ Mouse
Otubain1 DUB [230] Stabilization ✓ ✓
USP10 DUB [227] Stabilization ✓ ✓
USP29 DUB [229] Stabilization ✓
USP42 DUB [228] Stabilization ✓ ✓
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role for the ubiquitination function of MDM2/MDMX in the regulation
of p53, although the present information makes it difﬁcult to distin-
guish a role for the E3 activity from an alternative function for dimeriza-
tion — such as the regulation of MDMX subcellular localization [62,63],
for example. Furthermore, while an intact MDMX RING is required in
the embryo, this domain appears to be unnecessary in adult tissue
[30]. Indeed, MDM2 can restrain p53 activity without any MDMX in
the adult, to some extent [64], but the reciprocal is not true [65],
suggesting that MDM2 has the predominant role in this partnership.
Nevertheless, overexpression of either MDM2 or MDMX can play a
clear role in preventing p53 function and enhancingmalignant develop-
ment in several tumor types [66–69].
4. Regulation of MDM2/MDMX activity
Given the key role played by MDM2/MDMX in controlling p53, it is
not surprising that the regulation of their activity is controlled through
multiple systems. MDM2 is a transcriptional target of p53, resulting in
a negative feedback loop where p53 can induce the expression of its
own negative regulator. Interestingly, however, maintenance of low
basal p53 levels does not depend on the ability of p53 to transcriptionally
activate MDM2, and other transcriptional regulators of MDM2 such as
NFAT1 have been described [70]. While p53 function is not required for
MDM2 expression in normal cells, an elegant study in zebraﬁsh showed
that the transcriptional activity of p53 (and presumably the activation of
MDM2) is necessary to reduce p53 levels following the resolution of a
stress response [71]. MDMX has also been shown to be regulated by
p53, although the extent of activation is far weaker [72] and less general
[73] than that seen with MDM2. MAPK signaling has been reported toinduceMDMX transcription [74], but in general themechanisms regulat-
ingMDMXexpression are notwell understood. Interestingly,MDMXhas
also been shown to contribute to the ability of p53 to activate the expres-
sion ofMDM2 [75], thereby enhancing p53 degradation through an indi-
rect mechanism. Polymorphisms in MDM2 [76] and MDMX may
regulate their expression, while splice variants of each protein are also
associated with differential activities [77]. There is, therefore, ample op-
portunity for the regulation ofMDM2 andMDMX at the level of gene ex-
pression. However, it seems that critical control is exerted at the level of
post-translational modiﬁcations, which regulate protein function, inter-
action, localization and stability.
5. Modiﬁcations of MDM2/MDMX
A multitude of post-translational modiﬁcations on both p53 and
MDM2/MDMX, contribute to the regulation of p53 stability. In addi-
tion to the regulation of p53 with ubiquitin and other ubiquitin-like
proteins already discussed, MDM2 and MDMX are also actively con-
trolled through these modiﬁcations.
The E3 activity of MDM2/MDMX is not conﬁned to the targeting of
p53, and ubiquitination and degradation of all the players in this system
have been described. MDM2 can ubiquitinate itself, although E3 defec-
tive MDM2 proteins remain unstable in cells, suggesting that another
E3 can also drive the turnover of MDM2 (discussed further below).
MDMX is efﬁciently ubiquitinatedwhen in complexwithMDM2 [78], al-
though p53 is the preferred target of the E3 activity, andMDMXbecomes
stabilized in the presence of p53. High levels of MDMX can inhibit the
degradation of p53 by MDM2, and the E3 activity is likely to be limited
by the level of MDM2 in most cells [62]. In many cases it seems that























































Fig. 1. a: Regulation of p53 by ubiquitination. p53 and MDM2 form an auto-regulatory
feedback loop, where p53 induces transcription of MDM2, which dimerizes with
MDMX, forming an active E3 ligase. BothMDM2 andMDMX can repress the transcription-
al activity of p53 (independently of ubiquitination), promote p53 nuclear export via
mono-ubiquitination or poly-ubiquitinate p53 (in some cases aided by E4 ligases) causing
its degradation. Cytoplasmic p53 can exert a variety of activities (discussed in the text) or
be poly-ubiquitinated and degraded by E4 ligases (E4s). Ubiquitination of p53 can be
counteracted by several de-ubiquitinating enzymes. b: Feedback loop between p53 and
MDM2/MDMX during stress response. In unstressed cells, p53 is kept inactive by both
transcriptional inhibition and proteasomal degradation. Stress causes MDM2/MDMX to
release p53 and increase auto-degradation. This leads to p53 accumulation, resulting in
cell cycle arrest and other p53 responses. If the stress can be resolved, the cellsmay return
to the pre-stress state. If the p53 activating signal cannot be alleviated, p53 initiates
apoptosis or senescence.
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MDMX.
MDM2 is also modiﬁed by other ubiquitin like proteins. SUMO-1
modiﬁcation of MDM2 targets its N-terminus (between amino acids
134 and 212) through a mechanism that does not require the RING do-
main of MDM2 and is promoted by p14ARF [79]. Nedd8 modiﬁcations
of MDM2 have also been reported and are thought to increase MDM2
stability. This is counteracted by the NEDP1 which de-neddylates
MDM2 leading to its destabilization [80]. MDMX has also been shown
tobe SUMOmodiﬁed [81], although the signiﬁcance of thismodiﬁcation
is not yet clear.
6. Phosphorylation in the regulation of p53 stability
p53, MDM2 and MDMX can be phosphorylated on many sites by
numerous kinases and these modiﬁcations can be key in the activa-
tion of the p53 signaling network. The regulation and consequences
of these phosphorylation events are a complex ﬁeld that we can
only brieﬂy touch on here. However, several excellent reviews onthis topic that provide a much deeper description of this area have
been published recently [82–85].
An excellent example of the complexity of phosphorylation path-
ways in the control of p53 is provided by the response to DNA damage,
which promotes phosphorylation of several sites on p53, including ser-
ine 15 by DNA-PK [86] and ATM [87], and serine 20 via Chk2 [88,89].
While these phosphorylation events have been implicated in the stabi-
lization of p53, abrogating these modiﬁcations by mutating the target
amino acids on p53 – including serine 15 and 20 – does not prevent
p53 stabilization after induction of DNA damage in tissue culture
[90–92]. Furthermore, pointmutation of serine 18 inmice (homologous
to human serine 15) does not have a strong effect on p53 stabilization or
tumor formation in vivo [93,94]. Knock in mice expressing p53 with a
serine 23 to alanine substitution (homologous to human serine 20)
show reduced accumulation of p53 after gamma irradiation in several
tissues and increased incidence of long latency B cell lymphomas, al-
though again the expression of this phosphorylation site mutant p53
has only a modest phenotype [95,96]. Mutation of both these residues
(18 and 23) to alanine in a knock in model also causes partial defects
in the p53 response and a spectrum of tumors distinct from p53 loss
[97]. From these and a large number of additional studies (e.g. analysis
of serine 389 [98–101]) it seems clear that individual phosphorylation
modiﬁcations of p53 contribute to, but are not essential for the activa-
tion of p53 after DNA damage.
DNA-damage induced phosphorylation of MDM2 also plays an im-
portant role in the regulation of the p53 response. For example, phos-
phorylation of MDM2 on S17 (by DNA PK [102]) reduces the afﬁnity of
MDM2 towards p53, preventing the degradation and nuclear export of
p53, and so allows for the induction of a p53 response. Phosphorylation
of MDM2 on multiple sites (S386, S395 S407, T419, T425 and S429) by
ATM [103] does not alter the interactionwith p53, but reduces the ability
of MDM2 to homodimerize by regulating the function of both the RING
and the acidic domain [104,105]. Substituting all 6 ATM target residues
to alanine (6A) delays the stabilization of p53, while the substitution of
aspartic acids at these 6 sites (6D), which canmimic phosphorylation, re-
duces p53 poly-ubiquitination — again without altering the afﬁnity of
MDM2 to p53 [104]. Furthermore, phosphorylation of S395 alone has
been reported to inhibit MDM2 dimerization [104]. In vivo, the ability
to phosphorylate S394 in mice (homologous to human S395) is neces-
sary for DNAdamage-induced p53 activation.Mutating this residue to al-
anine (S394A) renders knock inmice radioresistant to a similar extent as
p53 null mice and these animals also develop T cell derived lymphomas
[106]. Interestingly the corresponding phosphomimic mice (S394D) are
viable and respond essentially normally to DNA damage, suggesting
that either the aspartic acid substitution does not completely mimic
phosphorylation, or that further DNA damage induced signals are re-
quired for a complete activation of the DNA damage response. However,
the defect in ubiquitination of p53 does not seem to reﬂect an overall re-
duction in E3 ligase activity, since bothMDM26A and 6DdegradeMDMX
as efﬁciently as wild type MDM2, and show a comparable level of
auto-ubiquitination [103].
Interestingly, the ATM-mediated phosphorylation at S395 also in-
creased the binding of MDM2 to p53 mRNA, promoting p53 synthesis
and suppressing MDM2's E3 ligase activity towards p53 and so
resulting in a switch from inhibition to activation of p53 [38].
Finally, phosphorylation of MDMX also plays an important role in
signaling to p53. Stress induced phosphorylation of MDMX by Chk2 re-
sults in 14–3–3 binding and nuclear accumulation of MDMX [107,108],
which – unlike MDM2 – does not contain its own nuclear localization
signal. Both Chk2 and ATM phosphorylation of MDMX can promote
the MDM2-mediated degradation of MDMX [109,110] — which is nor-
mally a stable protein in undamaged cells. Interestingly, mutations of
phosphorylation sites in MDMX can inhibit the ability to be degraded
by MDM2, without impeding MDM2's binding. These mutants lead to
a situation where MDMX is no longer sensitive to degradation by
MDM2, but the ability of the MDM2/MDMX complex to target p53
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cient p53 degradation under both basal and stressed conditions [111].
The complexity of regulation by phosphorylation is further en-
hanced by the action of the Wip1 phosphatase, itself the product of a
p53-inducible gene. Wip1 has been shown to dephosphorylate both
MDM2 and MDMX [112–114] resulting in decreased p53 levels and
activity.
7. Other modiﬁcations to regulate p53
In addition to phosphorylation, several other post-translational
modiﬁcations play an important role in ﬁne-tuning the p53 response.
Whilemono-methylation of p53 onK370 (by SMYD2 [115]) andK382
(by SET8 [116]) suppresses its transcriptional activity, di-methylation of
K370 or K382 activates p53 by binding of PHF20, which protects it
from MDM2 mediated ubiquitination [117]. Acetylation of lysines on
p53 by p300/CBP prevents the subsequent ubiquitination of p53 by
MDM2, since these modiﬁcations on the same lysine are mutually ex-
clusive [118]. Furthermodiﬁcations of p53, such as prolyl isomerization
[119] and glycosylation [120], may also contribute to the regulation of
p53 stability and activity. Knock in studies have shed some light on
the role of isomerization of p53, which in vivo seem to be dispensable
for the tumor suppressive activity [121]. The extent to which MDM2
and MDMX may be controlled by these modiﬁcations has not yet been
explored.
8. Chasing the tail of p53 regulatory loops
Many of the regulators of p53 are themselves regulated by p53,
forming complex positive and negative feedback loops [122]. As men-
tioned, p53 directly activates the transcription of MDM2 [123] and to
a lesser extentMDMX [72,73]. PirH2 [124] and Cop1 [125] transcription
is also induced by p53 and, as discussed above, the phosphataseWip1 is
a p53 target gene and can dephosphorylate both MDM2 and MDMX
[112–114]. All these establish negative feedback loops to induce efﬁ-
cient p53 turnover and allow cells to return to an unstressed state
once the cause of p53 induction is removed. An interesting example of
a positive feedback loop is the ability of the p53 inducible protein
PIDD to promote caspase 2-dependent cleavage of MDM2 [126]. Re-
moval of the RING domain of MDM2 by PIDD results helps to sustain
p53 activity following DNA damage.
9. MDM2/MDMX binding partners that inhibit p53 degradation
While DNA damage signaling provides an interesting example of
how p53 can become activated, it is clear that other stress signals
can control MDM2 and MDMX activity through quite independent
mechanisms. Several proteins that bind MDM2 and play a role in reg-
ulating its activity in response to oncogene activation or ribosomal
stress have been described. Of these, the best studied are p14ARF
(p19ARF in mouse) and various ribosomal proteins, which can all di-
rectly inhibit MDM2's E3 activity towards p53.
Aberrant signaling by several oncogenes including Ras [127], c-Myc
[128], E2F1 [129], ß-catenin [130] and NMI [131] leads to an induction
of ARF expression, either through transcriptional activation or stabiliza-
tion of the ARF protein. While ARF is a highly stable protein in tumor
cells, it is rapidly degraded in normal cells through the activity of ULF,
which promotes ubiquitin dependent degradation of ARF [132] — a
function that is inhibited by the oncogenic activity of Myc. The induc-
tion of ARF leads to its binding to MDM2, and stabilization and activa-
tion of p53. The importance of this function of ARF is supported by the
observation that tumors arising in response to the loss of ARF do not re-
quire p53 loss [133]. Interestingly, while p53 ubiquitination is inhibited
by ARF, MDM2 ubiquitination is not affected, suggesting that ARF bind-
ing does not completely incapacitate the E3 activity of MDM2 [134].Along similar lines, stress caused by an imbalance in ribosome bio-
genesis or ribosomal stress (which can be induced by perturbation of nu-
clear import of ribosomal proteins [135], expanded CAG RNAs associated
with polyglutamine toxicity [136] and metabolic ﬂuctuations [137,138])
can lead to the release of free ribosomal proteins (RPs) in the nucleus.
Like ARF, these can bindMDM2 and inhibit p53 ubiquitination, although
the binding requirements on p53 for ARF and the different ribosomal
proteins are subtly different. As with phosphorylation, the full wealth
of publications about the impact of ribosomal subunits on p53 activity
lies beyond the scope of this review, but has been more fully discussed
in several recent publications [138–140]. A large number of ribosomal
proteins can inﬂuence MDM2 activity, including RPL5 [141], RPL11
[142,143] (which can also be regulated by increased translation in re-
sponse to ribosomal stress [144]), RPL23 [145], RPL26 [146], RPS7
[147,148], RPS7L [149], RPS14 [150] and RPS25 [151]. As observed with
ARF, binding or association with RPs does not necessary inactivate
MDM2 but, much like phosphorylation after DNA damage, alter its spec-
iﬁcity. For example association of RPL11 withMDM2 leads to a switch in
activity of MDM2 from p53 towards MDMX, resulting in MDMX degra-
dation [152].While depletion of theseMDM2-interacting ribosomal pro-
teins can dampen the ability to induce p53, inhibition of one ribosomal
subunit in isolation can also trigger ribosomal stress, and thereby lead
to the stabilization of p53 through the activity of other ribosomal compo-
nents. The protection of free ribosomal proteins from degradation – in
particular L5 and L11 – has been shown to be critical for the activation
of p53 [153]. Importantly, the ability of MDM2 to bind L5 and L11 is nec-
essary for the induction of p53 in response to ribosomal stress (but not
DNA damage), and is required for full protection fromMyc-induced can-
cers [154]. Mutations disrupting RPL5 and RPL11, but not ARF binding to
MDM2 have been observed in human cancers [155], again supporting
the importance of signaling through this pathway in the protection
from tumor development. Interestingly someof these ribosomal proteins
(RPL26 [146] andRPS7 [148]) are themselves degraded byMDM2, and in
the case of RPL26 further complexity is introduced by the observation
that this ribosomal protein controls p53 mRNA translation, an activity
that is inhibited byMDM2 [146]. Other nucleolar proteins also contribute
to the regulation of p53 stability, including nucleostemin [156] and PICT1
(GLTSCR2), which functions by both enhancing the RPL11/MDM2 inter-
action [157] and direct p53 binding [158]. Nucleophosmin has also been
reported to bind MDM2 after UV-induced DNA damage, reducing the
p53–MDM2 interaction and thereby further stabilizing p53 [159].
While the nucleolar proteins and ARF can function to inhibit MDM2
independently in response to different signals, there is evidence for co-
operation between different ribosomal proteins [160] as well as be-
tween ARF and L11 [161]. Indeed, there is evidence that ARF can
trigger nucleolar stress that ARF functions, at least in part, through
L11. Exactly how ARF and the ribosomal proteins inhibit MDM2 is not
clear. All these proteins bind to the central region (and not the RING do-
main) of MDM2, a domain of MDM2 that is known to be important for
p53 degradation [162], and can inhibitMDM2's E3 activity towards p53.
Furthermore, the interaction of MDM2with ARF can lead to the dissoci-
ation of theMDM2/p53 complex by relocalizingMDM2 to the nucleolus
[142]. ARF also promotes enhanced SUMOylation of MDM2 [79], al-
though the extent to which this modiﬁcation is necessary to mediate
the ARF repressive effects on MDM2 remains to be determined. Inter-
estingly, while de-SUMOylation of MDM2 by SUSP4, a SUMO speciﬁc
protease, resulted in an increased MDM2 activity, this led to increased
auto-ubiquitination and degradation of MDM2, and so the accumula-
tion of p53 [163]. Whether ribosomal proteins have a similar ability to
drive the SUMOylation of MDM2 is not known.
While ARF and ribosomal proteins are the best understood inhibi-
tors of MDM2, numerous other proteins that can bind p53 and protect
it from MDM2-mediated degradation have been described. One of
these is NUMB, which was initially described as a MDM2 interacting
protein [164] but has since been shown to bind to both p53 and
MDM2, thereby preventing ubiquitination and degradation of p53
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[166], leading to the dissociation of the p53–MDM2 complex, stabiliza-
tion of p53 and degradation of NUMB instead.
Like NUMB, other important regulators of cell behavior, such as
PML [167,168], Smad1 [169], SnoN [170], Pin1 (which functions
through proline isomerization of p53 [119]), HEXIM1 [171], and
TRIAD1 [172] have also been described to impact MDM2's E3 ligase
activity. Each of these regulators is subject to control mechanisms,
and the existence of loops involving the mutual regulation of various
components of these systems creates a dizzyingly complicated net-
work through which the p53 response can be controlled.
Less is known about the binding partners that control MDMX, al-
though the importance of phosphorylation-dependent 14–3–3 binding
has already been mentioned. Interestingly, although the ribosomal pro-
teins have not been described to bind MDMX, ARF can interact with
MDMX, causing its sequestration to the nucleolus and resulting in the ac-
tivation of p53 [173]. Also, 5S rRNA binds efﬁciently to the RING domain
of MDMX, but only very weakly to MDM2, and is important for
protecting MDMX from MDM2-mediated degradation. However, the
regulation of thismechanism during the stress response remains unclear
[174].10. MDM2/MDMX binding partners that promote
p53 ubiquitination
Mounting evidence in the literature supports the notion that several
E3 ligases are assisted by a ubiquitin chain assembly factor (E4), which
supports E3 ligases by extending ubiquitination chains to increase over-
all performance. Although it is technically difﬁcult to differentiate be-
tween an E3 ligase co-factor and an E4 ligase, several E4 enzymes for
p53 have been proposed. Other MDM2/MDMX binding proteins may
also enhance the ubiquitination of p53 through different mechanisms.
One of those is TCTP, which acts as an antagonist to NUMB by competing
with NUMB for binding to p53–MDM2, thereby inhibiting auto-
ubiquitination of MDM2 and promoting degradation of p53 [175]. Inter-
estingly TCTP is itself transcriptionally repressed byp53, adding to the in-
tricacies of the feedback regulation.10.1. p300
p300 and its close paralog CBP have been described to exhibit E4 ac-
tivity towards p53 in vitro and in cells [176] by accepting mono-
ubiquitinated p53 as a substrate, rapidly extending the ubiquitin chain
and causing increased turnover of p53 [176]. This activity is indepen-
dent and separable from p53 acetylation by p300/CBP and is exclusive
to the cytoplasm. These observations are nicely consistent with a
model in which at low levels MDM2 promotes mono-ubiquitination,
SUMOylation by PIASy and nuclear export of p53 [57], which then can
subsequently be poly-ubiquitinated by p300, leading to its proteasomal
degradation in the cytoplasm. By contrast, high levels of MDM2 pro-
mote the polyubiquitination and nuclear degradation of p53 [40].10.2. UBE4B
UBE4B, the mammalian homolog of UFD2 (the ﬁrst E4 ubiquitin li-
gase to be identiﬁed in yeast), has been shown to interact with both
MDM2 and p53, and can extend the poly-ubiquitin chain assembled
by MDM2 on p53 both in vitro and in cells [177]. A RING-like domain,
known as a U-box, in UBE4B is indispensable for its function as an E4
ligase towards p53. Deletion of UBE4B in vivo results in early embry-
onic death that is accompanied by induction of apoptosis in the heart,
where UBE4B is exclusively expressed during embryogenesis [178].
However, it is not clear whether this apoptosis can be attributed to
stabilization of p53.10.3. Gankyrin
Gankyrin, an akyrin repeat containing protein, associates with the
ATPase subunit of the 26S proteasome and can also control the
ubiquitin ligase activity of MDM2 on p53. In cells, overexpression of
Gankyrin increases the ratio of poly- versus mono-ubiquitinated p53
as well as increasing the interaction of ubiquitinated p53 and MDM2
with the proteasome. Therefore, Gankyrin probably enhances delivery
of ubiquitinated p53 to the proteasome, in addition to increasing
MDM2 activity [179].
10.4. Yin Yang 1
Yin Yang 1 not only enhances poly-ubiquitination of p53 to a similar
extent as p300, but also increases the afﬁnity of MDM2 towards p53,
thereby potentiating its ability to promote the ubiquitination of p53
[180]. Furthermore, Yin Yang 1 binds p300 [181] and may therefore re-
cruit p300 to further boost p53 poly-ubiquitination.
11. Signaling to enhance p53 turnover
While stress signals function to inhibitMDM2and so stabilize p53, the
ability to dampen or impede p53 function may also be important under
certain conditions. Phosphorylation of MDM2 by AKT can induce
MDM2 function and so prevent stabilization of p53 under conditions of
growth factor survival signaling [182–184]. AKT can also phosphorylate
MDMX to promote 14–3–3 binding, although unlike DNA damage-
induced induction of MDMX-14–3–3 binding, the result is the stabiliza-
tion of MDMX and MDM2 [185]. While the details of how 14–3–3
controls MDMX remain to be elucidated, the overall message is that
AKT functions to enhanceMDM2 activity, and so inhibit p53. Interesting-
ly, a recent study has shown that the AKT signaling pathway is important
to prevent p53-induced inhibition of cell cycle progression under condi-
tions of normal cell growth [186]. The phosphorylation of the central re-
gion of MDM2 by kinases such as GSK-3 may also help to promote p53
degradation by enhancing the interaction of MDM2with the proteasome
[187].
Other protein interactions can promote the ability of MDM2 to de-
grade p53 include Pax3 [188], Twist [189], Niban [190] (which works
by releasing MDM2 from nucleophosmin), Smurf1/2 [191] (which func-
tions by enhancing the MDM2/MDMX interaction) and TCTP [175]
(which binds MDM2, preventing NUMB binding and inhibiting auto-
degradation). In another variation on this theme, the E3 ligase RFWD3
can synergize with MDM2 in the ubiquitination of p53, but this results
in the formation of shorter ubiquitin chains that cannot be recognized
by the proteasome [192]. RFWD3 therefore contributes to the DNA-
damage induced stabilization of p53 by – paradoxically – enhancing
ubiquitination.
12. Additional E3s for p53
The molecular and genetic evidence supporting the major role for
MDM2/MDMX in targeting p53 for degradation is overwhelming.
However, the complexity of p53 regulation suggests that additional
factors can contribute to the control of p53 stability and several E3 li-
gases have been reported to ﬁll this gap.
12.1. Pirh2
Like MDM2, Pirh2 is a RING E3 ligase that binds and ubiquitinates
p53, and is itself transcriptionally activated by p53 [124]. Interesting-
ly, Pirh2 ubiquitinates p53 on several lysine residues, including K101,
K164, K292, K305, K357, K382 and K386 [193]. However, in vitro
Pirh2 and MDM2 show differences in lysine speciﬁcities, with only
Pirh2 able to modify K168, an activity that opposes the acetylation
of this site by p300/CBP. Acetylation of K168 is a prerequisite for
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is consistent with a role of Pirh2 in repressing p53 function. Mice de-
leted of Pirh2 [195] have highlighted a role for Pirh2 in the regulation
of p53 turnover in response to DNA damage.
12.2. ARF-BP1
ARF-BP1, also known as MULE/HectH9/HUWE1, is a HectE3 ligase
[196] that ubiquitinates and targets p53 for degradation. Deletion of
ARF-BP1 leads to embryonic lethality around day E14.5, accompanied
by increased levels of p53 and increased apoptosis in some tissues.
Speciﬁc deletion of ARF-BP1 in pancreatic β-cells resulted in an
age-dependent diabetic phenotype due to a reduction of the beta-cell
population in a p53 dependent manner [197]. Interestingly, ARF-BP1
was identiﬁed as a binding partner for ARF,which acts as a negative reg-
ulator for both ARF-BP1 and MDM2.
12.3. CHIP
CHIP was initially described as an Hsp70 associated E3 ligase that
has a role in the chaperone-assisted quality control, targeting – among
other things –mis-folded and aggregated proteins for proteasomal deg-
radation. Some p53 mutations cause conformational instability of the
protein, suggesting that CHIP may have an effect on mutant p53 stabil-
ity. Indeed, CHIP interacts with bothmutant andwild-type p53, and can
reducemutant (and to a lesser extentwild type) p53 levels and half-life
[198]. More recent studies have highlighted a role for CHIP regulating
p53 in cardiomyocytes after hypoxic stress [199].
12.4. Trim24
Trim24 is another RING E3 that was identiﬁed as a p53 binding
partner [200]. Ubiquitination and degradation of p53 by Trim24 are
dependent on the RING domain, and depletion of Trim24 leads to an
increase in p53 in various cell lines. Mutation of bonus, the drosophila
homolog of Trim24, resulted in enhanced apoptosis in the wing imag-
inal disks, a phenotype that could be rescued by p53 depletion. These
results suggest that Trim24 is necessary to down-regulate p53 activi-
ty in vivo and are particularly interesting in light of the fact that Dro-
sophila does not have MDM2, despite the general assumption that
MDM2 and MDMX binding domains co-evolved with p53 [201].
Further studies have shown that Trim24 can control p53 activity
in human embryonic stem cells [202], where phosphorylation of
p53 on lysine 373 in response to retinoic acid disrupts the degrada-
tion by Trim24.
12.5. E4F1
E4F1 is part of the polycomb repressive complex 1 (PRC1), and can
induce cell-cycle arrest in a p53 dependentmanner [203]. Interestingly,
E4F1 ubiquitinates p53 through K-48 linked poly-ubiquitination [204],
targeting lysines (K319, K320, K321) that are distinct from the target ly-
sines of MDM2. The consequence of ubiquitination by E4F1 is not to
drive degradation, but to promote the transcription of p53 dependent
cell-cycle arrest genes. The involvement of E4F1 in several independent
anti-proliferative pathways hasmade the analysis of in vivo phenotypes
complicated, although recent analysis of conditional E4F1 knockout
mice has shown that it is clearly involved in the BMI1/ARF/p53 path-
way. However, as with all these E3s, the functions of E4F1 are likely to
extend beyond the regulation of p53 [205].
12.6. Other ubiquitin ligases for p53
In addition to those discussed above, a number of other ubiquitin
ligases have been implicated in the regulation of p53 stability. These
includeMSL2 andWWP1, which increase the cytoplasmic localizationof p53 [206,207] but do not affect (MSL2) or even increase (WWP1)
p53 stability, and Hades, a RING E3 ligase that interacts with p53 in
the mitochondria and thereby inhibits a p53-dependent mitochondri-
al cell death [208]. Ubc13 is an E2 enzyme that directly assembles K63
chains on p53, leading to its monomerization and cytoplasmic locali-
zation [209]. Additionally, Carp1, Carp2 [210], the endoplasmatic re-
ticulum located RING E3 ligase Synoviolin [211] and the ubiquitin/
SUMO E3 ligase TOPORS [212] have all been described to ubiquitinate
p53. Although Cop1 has been reported to be an E3 ligase for p53
[125], later studies have not found Cop1 mediated degradation of
p53 in vivo [213]. Finally, the RING E3 ligases Trim28 [214] and
Trim39 [215] have been shown to target p53 for ubiquitination. Bio-
chemical evidence supports the role of each of these proteins in the
ﬁne-tuning of p53 activity, although their overall importance in vivo
needs to be further investigated.
Finally, we come to the Cullin-RING ubiquitin-ligases. These are
modular multi subunit enzymes comprising an active E3 ligase, either
RBX1 (also known as ROC1) or RBX2, bound to one of the seven Cullin
family members (Cullin-1, -2, -3, -4A, -4B, -5 and -7), and a substrate
speciﬁc receptor, either directly or via adapter proteins. Cullin E3s are
known to play important roles in the cell cycle, transcription, signal
transduction and are often deregulated in cancer (reviewed in [216]).
Several factors of the Cullin RING E3 ligase family have been implicated
in inﬂuencing p53 activity, including Cullin 1 [217], Cullin 2 [218], Cullin
4a [219,220], Cullin 5 [218,221,222], Cullin 7 [223], Cullin 9 [46] and
their common adaptor proteins Skp1 [217,224], Skp2 [225], the F-box
protein JFK [217] and DDB1 [226]. However, the relevance of their re-
spective impact on p53 remains to be determined.
13. De-ubiquitination of p53 and MDM2
It is clear that ubiquitination, like most other post-translational
modiﬁcations, is a highly dynamic and reversible signal. Therefore it
comes as no surprise that several de-ubiquitinating enzymes (DUBs)
have been described that can balance the p53 ubiquitin equation,
adding further possibilities for ﬁne-tuning the p53 response.
13.1. USP10
USP10 was identiﬁed “by serendipity” [227] as a p53 interacting
protein and functions to regulate p53 stability and localization by
counteracting the effects of MDM2. Following genotoxic stress, USP10
is phosphorylated by ATM and translocated to the nucleus, where it
can deubiquitinate and stabilize p53. Interestingly, USP10 also displays
deubiquitinating activity towardsmutant p53, and somay serve to pro-
mote the oncogenic effects of mutant p53 in tumor cells.
13.2. USP42
USP42 also targets p53 [228], but its main role appears to be to
counteract residual p53 ubiquitination immediately after the induc-
tion of genotoxic stress, decreasing the response time of the p53
pathway. USP42 does not affect the basal levels of p53 in unstressed
cells, presumably because of the high activity of the E3 ligases that
target p53. During the initial phases of the stress response, USP42, ac-
celerates but not increases the overall stabilization of p53. There is, as
yet, no evidence that this function of USP42 can be regulated.
13.3. USP29
USP29 is transcriptionally activated in response to oxidative stress
through a mechanism that involves the nuclear localization of JTV1.
This DUB then de-ubiquitinates and stabilizes p53, so contributing
to the full activation of the p53 target gene PUMA and consequent ap-
optosis [229].
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The mechanism of activation for Otub1, another de-ubiquitinating
enzyme for p53, is less well understood [230], since the catalytic cys-
teine of Otub1 is not necessary for this deubiquitination. It is possible
that the activity of Otub1 reﬂects the inhibition of UbcH5/MDM2,
rather than a classic de-ubiquitination function.
14. Regulating the regulators
14.1. The E3s
Although it is clear that MDM2 can ubiquitinate and degrade itself,
catalytically inactive MDM2 (C462A) retains the short half-life charac-
teristic of the wild type protein [61], indicating that other E3 ligases
can targetMDM2. Several E3 ligases for MDM2have been described, al-
though none of them has been carefully investigated in vivo. Of speciﬁc
interest is SCF β-TRCP, an F-box protein that binds and degrades both
wild type and C464A (equivalent to C462A in mouse) MDM2 in a DNA
damage and cell-cycle dependent manner [231]. Trim13, also known
as RFP2, has also been shown to harbor E3 ligase activity towards
MDM2 in vitro and in cells [232]. An increase in Trim13 levels after ion-
izing radiation could support a mechanism where upon induction of
stress, Trim13 changes from auto-degradation to ubiquitination of
MDM2, supporting the rapid stabilization of p53.
14.2. The DUBs
Just like p53, de-ubiquitination of MDM2 and MDMX also plays a
role in the control of p53 stability. USP7, also known as HAUSP, was ini-
tially described to de-ubiquitinate and stabilize p53 [233]. However,
soon it became clear that HAUSP functions mainly to de-ubiquitinate
and stabilize MDM2 [234] and MDMX [235]. DNA damage induced
phosphorylation of MDMX interferes with the MDMX/HAUSP interac-
tion, so allowing the degradation of MDMX and stabilization of p53.
The activity of HAUSP itself is also regulated by phosphorylation, with
speciﬁc dephosphorylation by the DNA-damage induced phosphatase
PPM1G leading to the down-regulation of HAUSP, destabilization of
MDM2 and activation of p53 [236]. DeletingHAUSP causes early embry-
onic lethality [237], which is accompanied by elevated levels of p53 and
reduced proliferation. Co-deletion of p53 did not completely rescue the
HAUSP null phenotype, but resulted in signiﬁcant developmental im-
provements. HAUSP therefore appears to function as a negative regula-
tor of p53, through the de-ubiquitination and stabilization of MDM2,
but also clearly functions through additional, MDM2-independent
pathways.
USP2a is anMDM2 interacting DUB [238], which de-ubiquitinates and
elevates the levels of MDM2, allowing for an increased ubiquitination of
p53. Inhibition of USP2a in response to Frizzled 8-associated Anti-
proliferative Factor (APF) was shown to contribute to an increase in
p53 levels and activation of growth arrest [239]. USP2a also de-
ubiquitinates and stabilizes MDMX [240]. Finally, USP4 has been
shown to de-ubiquitinate and stabilize ARF-BP1, leading to reduced
p53 levels and a dampening of p53 activity [241].
14.3. MicroRNAs that regulate MDM2
MicroRNAs (miRNAs) are endogenously expressed short noncoding
RNAs that can play important regulatory roles in gene silencing, transla-
tional repression, mRNA cleavage, and mRNA decay. They are involved
inmultiple biological processes, including the response to environmen-
tal stresses and cancer development. Several microRNAs targeting
MDM2 have been identiﬁed, including miR143/145 [242], miR605
[243], miR25, andmiR32 [244]. The transcription of miR25 and 32 is in-
duced by E2F-1 and cMyc, leading to a reduction of MDM2 protein
levels through direct binding to 3-UTR of MDM2 mRNA. This stabilizesp53 protein levels and results in decreased cell proliferation and cell
cycle arrest. BothmiR143/145 andmiR605 can be induced by p53, lead-
ing to decreased MDM2 protein levels and increased p53 function, con-
stituting a positive feedback loop that may help in allowing the robust
activation of p53.15. Drugging the p53 degradation pathway
Stabilization of p53 is critical for cells to respond to stress and limit
cancer development. Cancer cells almost all lack the ability to activate
a p53 response, and so continue to proliferate and survive despite
their exposure to various forms of oncogenic stress, including oncogene
activation, hypoxia and loss of normal environment. Indeed, numerous
studies have shown that increasing p53 levels can lead to tumor regres-
sion through the activation of apoptosis or senescence [245–247], either
in the incipient tumor cell or through non cell-autonomous pathways
[248]. The stabilization of p53 in cancers that retain wild type p53 is
therefore an attractive strategy for therapy.
Themain focus of these studies so far has been to develop smallmol-
ecule inhibitors of MDM2 dependent degradation of p53. There is sub-
stantial evidence that MDM2 and MDMX can contribute to tumor
development, and that this reﬂects their ability to inactivate p53. Indeed
several tumors that retain wild type p53 show evidence of MDM2 or
MDMX overexpression, including gliomas, soft tissue tumors andmela-
noma [66,68,69,249,250]. The consequences of MDM2 andMDMX inhi-
bition have been assessed using genetically engineered mouse models,
using acute restoration of p53 in adult MDM2 or MDMX deﬁcient mice
[64,65]. Interestingly, the absence of MDM2 resulted in a fatal response
to p53, raising some concerns about the general toxicity of systemic
treatment with MDM2 inhibitors. However, while lack of MDMX
resulted in the activation of p53, this was tolerated by the mice and
could be reversed. Importantly, the absence of MDMX enhanced the
therapeutic effect of p53 restoration in tumors, supporting the potential
for MDMX as a therapeutic target.
A number of approaches to developing inhibitors of p53 degrada-
tion have been explored (again a broad topic that is more fully
reviewed in [251]). These include the development of drugs that pre-
vent the p53/MDM2 or p53/MDMX interaction, inhibit MDM2's E3 li-
gase activity, block the delivery of p53 to the proteasome or even
modulate the activity of the DUBs that regulate p53 or MDM2.
A number of smallmolecules have been developed that can occupy a
hydrophobic pocket inMDM2's p53 binding site, thereby disrupting the
MDM2 p53 interaction. The ﬁrst of these, Nutlin 3A, has proven to be
highly speciﬁc in inducing arrest, apoptosis and cellular senescence in
both tissue culture and xenographedmousemodels [252,253] and a de-
rivative of this drughas been advanced to phase I clinical trials for adults
with leukemia [254]. A similar approach has led to the identiﬁcation of
small molecules such as RITA, which also prevent the p53/MDM2 inter-
action but function by binding the N-terminus of p53 [255]. Small mol-
ecule inhibitors of the p53/MDMX interaction have also been described
[256].
Direct inhibitors ofMDM2orMDM2/MDMXE3 activity can also pro-
mote p53 stabilization and activation,without necessarily inhibiting the
interaction of the two proteins [257–259]. The mechanism of action of
such inhibitors is less well understood, although some have been
shown to function by binding to the RING domain ofMDM2. Small mol-
ecules that induce the dimerization of MDM2 and MDMX can also pro-
mote p53 stabilization and activation, and may simultaneously inhibit
both MDM2 and MDMX [260]. Whether this will drive unacceptable
levels of toxicity remains to be determined.
Stapled peptides based on the p53 transactivation domain have also
been used to block both MDM2 mediated degradation [261,262] and
MDMXmediated repression of p53 [263], and a phage display based ap-
proach has yielded novel peptide derived activators of p53 that display
high binding afﬁnity to both MDM2 and MDMX [264]. Finally, small
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activate p53.
Most obviously, MDM2 inhibiting drugs could be used to activate
p53 in tumors that retain wild type p53. However, an alternative ap-
proach harnesses the inability of tumor cells containing mutant p53
to cease proliferation in response to MDM2 inhibitors. In this ap-
proach, activation of p53 could be used to protect normal cells that
retain wild type p53 from the toxic effects of mitotic poisons (through
the induction of a reversible cell cycle arrest). The chemotherapy
would therefore speciﬁcally target only the remaining cycling (mu-
tant p53 containing) tumor cells [266,267].
Finally, development of inhibitors of p53, potentially by activating
MDM2 E3 ligase activity, could also prove beneﬁcial as a chemo- and
radio-protective treatment where toxicity is related to the activation
of p53. Again, the approach depends on the protection of normal tis-
sue – in this case by transient inactivation of p53 – possibly allowing
for higher doses of irradiation to target p53 mutant cancer cells. The
potential beneﬁt of such an inhibitor is supported by mouse studies,
where a temporary inactivation of p53 renders normal tissues less
sensitive to apoptosis by irradiation, while leaving them competent
to antagonize oncogene activation by growth arrest and induction
of senescence [245].
The complexity of the systems that regulate p53 stability will pro-
vide many other potential drug targets, including other E3s and DUBs.
Although at an early stage, these studies have the potential to yield
powerful tools to help fully comprehend the complexity of the inter-
play between p53 and ubiquitination, and develop new, targeted
therapies for cancer treatment.
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